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3 Present address: CNRS UMR 8601, Paris, France.To decipher the mechanism involved in Grb14 binding to the activated ﬁbroblast growth factor
receptor (FGFR), we used the bioluminescence resonance energy transfer (BRET) technique and
the Xenopus oocyte model. We showed that Grb14 was recruited to FGFR1 into a trimeric complex
containing also phospholipase C gamma (PLCc). The presence of Grb14 altered FGF-induced PLCc
phosphorylation and activation. Grb14-FGFR interaction involved the Grb14-SH2 domain and the
FGFR pY766 residue, which is the PLCc binding site. Our data led to a molecular model whereby
Grb14 binding to the phosphorylated FGFR induces a conformational change that unmasks a PLCc
binding motif on Grb14, allowing trapping and inactivation of PLCc.
Structured summary:
MINT-8019680: Grb14 (uniprotkb:O88900) physically interacts (MI:0915) with FGFR1 (uniprotkb:P11362)
by anti tag coimmunoprecipitation (MI:0007)
MINT-8019693, MINT-8019727: Grb14 (uniprotkb:O88900) physically interacts (MI:0915) with FGFR1
(uniprotkb:P11362) by bioluminescence resonance energy transfer (MI:0012)
MINT-8019714, MINT-8019746: PLC gamma1 (uniprotkb:P19174) physically interacts (MI:0915) with
FGFR1 (uniprotkb:P11362) by bioluminescence resonance energy transfer (MI:0012)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction genesis [1]. FGF signaling is transduced through a family of fourFibroblast growth factors (FGF) are a family of more than 20
growth factors that are crucial regulators of vertebrate develop-
ment and modulators of tissue growth and differentiation. Muta-
tions in FGFs or dysregulations in FGF expression and action
result in developmental abnormalities and contribute to tumori-chemical Societies. Published by E
ergy transfer; FGF, ﬁbroblast
; MAPK, mitogen activated
PI3K, phosphatidylinositol 3
in tyrosine phosphatase 1B;
n
A.-F. Burnol).transmembrane tyrosine kinases. Ligand binding induces receptor
dimerization, phosphorylation and activation of the cytoplasmic
tyrosine kinase domain, and then initiation of various signal trans-
duction cascades [2]. Target proteins are recruited to the activated
receptor through the interaction between their Src-homology 2
(SH2) domains and speciﬁc phosphotyrosine residues on the
activated receptor, initiating signaling pathways such as Ras-mito-
gen activated protein kinase (MAPK), phosphatidylinositol 3 kinase
(PI3K)-Akt and phospholipase C gamma (PLCc) pathways [3].
Another protein, Grb14, was also shown to be recruited to the
activated FGF receptor (FGFR) [4]. Grb14 belongs to the Grb7
family of adaptors, which comprises Grb7, Grb10 and Grb14, which
are implicated in growth factor receptor signaling [5]. Grb14 is an
inhibitor of insulin signaling, which binds to the activated insulin
receptor tyrosine kinase domain and acts as a pseudosubstrate to
inhibit its catalytic activity [6,7]. The inhibition of FGF signalinglsevier B.V. All rights reserved.
4384 E. Browaeys-Poly et al. / FEBS Letters 584 (2010) 4383–4388by Grb14 was reported on ﬁbroblasts proliferation and on FGF-
induced Xenopus oocyte maturation [4,8,9]. This effect was attrib-
uted to the binding of the Grb14 SH2 domain to phosphorylated
tyrosine residues in the C-tail of the activated FGFR1 [4]. Two
residues in the C-terminal part of FGFR1 could potentially recruit
the Grb14 SH2 domain: Y766, which is the binding site for PLCc
[10], and Y776.
The aim of the present study was to elucidate the molecular
mechanisms involved in Grb14 inhibition of FGF-induced FGFR1
signaling. Our data allowed us to propose an original molecular
model whereby Grb14 recruitment to the FGFR-PLCc complex
inhibits FGF-induced PLCc activation.2. Material and methods
2.1. Expression vectors
Grb14-yellow ﬂuorescent protein (YFP) has been described pre-
viously [11], YFP-PLCc was a gift from Z. Wang. Human FGFR1
cDNA (gift from L. Claesson-Welsh) was cloned into phRluc-N1;
FGFR1 Y766F and K514A mutants were obtained using the Quick-
change site-directed mutagenesis kit (Stratagene).
2.2. Bioluminescence resonance energy transfer (BRET) experiments
Transfection of HEK293 cells and BRET analysis were performed
as described previously [11].
2.3. Xenopus oocyte experiments
Oocyte handling, microinjection of FGFR mRNA or puriﬁed GST-
fusion proteins, and germinal vesicle breakdown (GVBD) analysis
were performed as previously described [8]. To express FGFR, the
cDNA coding for the receptors were inserted into vector pSP64T
[12] to generate capped cRNAs (mMESSAGE mMACHINE kit, Ambi-
on), that were injected into oocytes. Since no suitable antibody was
available to immunoprecipitate FGFR, a PDGFR-FGFR chimera was
used, which was composed of the human extracellular domain of
the platelet derived growth factor (PDGF) receptor and the intra-
cellular domain of Pleurodeles waltlii FGFR1 (a newt), which is
highly homologous to the human receptors [13]. Such chimera
were previously used to study FGFR signaling in Xenopus oocytes
[8,12]. The chimera was stimulated with PDGF-BB (5 nM) for
5 min and immunoprecipitated with antibodies directed against
the extracellular part of the chimeric receptor (BD Transduction
Laboratories). Electrophysiological measurements were performed
using the standard two microelectrode voltage-clamp technique as
in [14].
2.4. Fusion proteins and peptides preparation
GST fusions for Grb14 and its SH2 domains were produced as
described previously [6]. The SH3 domain of PLCc (gift from Prof.
E.P. Kay) were produced as described [15]. Peptide PP (ETPSIPNPF-
PELC) from Grb14 N-terminus sequence was from Neosystem
(France). Peptide pY766 (SNQE(p)YLDLS) was a gift from P. Doherty
[16]. Peptides pY776 (PLDQ(p)YSPSF) and Y776 (PLDQYSPSF) were
synthesised by Merriﬁeld stepwise solid-phase synthesis on an Ap-
plied Biosystems A433 automated peptide synthesizer using Fast-
Fmoc chemistry described previously [17].
2.5. Immunoprecipitation and Western blot analysis
Proteins were extracted from cultured cells and oocytes and
analyzed as described, respectively in [11] and [8].2.6. In vitro measurement of binding afﬁnities
Binding of the ﬂuorescent 766pY peptide to GST, GST-Grb14,
and GST-PLCc-SH2 was measured using a 384-well microtiter
plate reader Envision 2101 (Wallac, PerkinElmer Life sciences
and Analytical Sciences, Turku, Finland) as described in [17].
2.7. Statistical analysis
Statistical analysis was carried out using a Student’s t-test for
paired values.
3. Results and discussion
3.1. Monitoring of FGFR–Grb14 interaction in living cells by BRET
Overexpression of Grb14 in mammalian cells and in the Xenopus
oocyte model inhibits FGF-induced cell proliferation [4,8,9]. We
thus ﬁrst aimed at conﬁrming the inhibitory role of Grb14 on
FGF signaling in a physiologically relevant model. As shown in
Supplementary Fig. S1, FGF-induced Akt phosphorylation was en-
hanced in mouse embryonic ﬁbroblasts (MEF) obtained from
Grb14 KO mice compared to MEF from wt mice. This inhibitory ef-
fect of Grb14 on Akt activation is likely to be involved in the in-
creased proliferation rate of Grb14 KO MEF cultured in the
presence of fetal bovine serum [18]. To better understand the
mechanism by which Grb14 inhibits FGFR signaling, we focused
our study on the Grb14–FGFR interaction. We used the BRET tech-
nology which allows the study of protein–protein interaction in
living cells. We previously used this technique to decipher the
interaction between the insulin receptor and Grb14 or the tyro-
sine-phosphatase PTP1B [11,19]. To investigate FGFR partner
recruitment, we ﬁrst validated the known FGFR–PLCc interaction
with this system. When expressed in HEK293 cells FGFR was con-
stitutively phosphorylated on tyrosine residues and FGF stimula-
tion did not further enhance this phosphorylation (Fig. 1A). FGFR
phosphorylation was not signiﬁcantly altered in the Y766 mutant
(in which only the PLCc binding site was mutated) but was sup-
pressed in the kinase-dead K514A mutant (Fig. 1B). This suggested
that FGFR was constitutively activated in HEK293 cells, possibly
due to an autocrine production of FGF by the cells or to the overex-
pression of the receptor. Co-expression of FGFR-renilla luciferase
(Rluc) and YFP-PLCc in HEK293 cells resulted in a robust BRET sig-
nal, which was abolished when using either the kinase-dead mu-
tant or the receptor mutated for the PLCc binding site (Fig. 1C).
Supporting the constitutive activation of FGFR expressed in
HEK293 cells, FGF stimulation did not modify FGFR-PLCc BRET
signal (Supplementary Fig. S2). These experiments conﬁrmed the
FGFR–PLCc interaction and the role of the FGFR Y766 residue for
PLCc recruitment, and validated the use of BRET to investigate
FGFR–Grb14 interaction in living cells.
Co-expression of FGFR-Rluc and Grb14-YFP resulted in a robust
BRET signal, indicating an interaction between the two proteins in
living cells (Fig. 1D). This signal was not detected when the FGFR
kinase-dead mutant was used (Fig. 1D). Formation of a Grb14-FGFR
complex was conﬁrmed by co-immunoprecipitation experiments
(Fig. 1E). Interestingly, the FGFR-Y766F mutant induced an inter-
mediate BRET signal (Fig. 1D), suggesting that this site was impli-
cated in the interaction, although it may not be the only binding
site. Since the FGFR Y766 residue was involved in the binding of
both PLCc and Grb14, we investigated the consequences of the
presence of Grb14 on FGFR–PLCc interaction. Co-expression of un-
tagged Grb14 slightly increased the BRET signal induced by the
FGFR-Rluc/YFP-PLCc interaction (Fig. 1F), showing that it did not
disrupt the complex. Since BRET depends not only on the distance
between the two partners but also on their relative orientation
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Fig. 1. FGFR interaction with PLCc and Grb14 in intact living cells. (A and B) FGFR autophosphorylation in HEK293 cells. HEK293 cells were transfected with the FGFR-Rluc or
the mutated constructs and stimulated or not with 50 ng/ml FGF1 and 100 lg/ml heparin when indicated. Cells lysates were immunodetected using anti-phosphotyrosine
antibodies (pTyr), b-actin to control protein loading or anti-Rluc to control receptor expression as indicated. (C, D and F) FGFR interactions were monitored by BRET in HEK293
cells expressing FGFR-Rluc constructs and either YFP-PLCc (C), Grb14-YFP (D) or YFP-PLCc and Grb14 (F). (E) HEK293 cells were co-transfected with FGFR-Rluc and Grb14-
YFP or empty vectors, and stimulated or not with 50 ng/ml FGF1 + heparin (100 lg/ml) for 15 min as indicated. Grb14-YFP was immunoprecipitated with anti-GFP antibodies
and the amount of FGFR co-precipitated was evaluated using an anti-Rluc antibody. The asterisk indicates a non speciﬁc band revealed by the anti-Rluc antibody. (G) HEK293
cells were transfected with the indicated expression vectors. Cell lysates were immunoprecipitated with anti-GFP antibodies and analyzed by Western blotting.
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presence of Grb14 could thus result from the formation of a
FGFR-PLCc-Grb14 ternary complex inducing a rearrangement in
the FGFR-Rluc/YFP-PLCc interaction. The presence of such a trimer
was investigated in HEK293 cells transfected with wt or mutated
FGFR-Rluc, YFP-PLCc and Grb14-Rluc. Co-immunoprecipitation
experiments were performed using anti-GFP antibodies. As shown
in Fig. 1G, PLCc co-precipitated both Grb14 and FGFR. When the ki-nase-dead FGFR mutant was expressed no interaction was de-
tected with PLCc, conﬁrming the BRET data, and Grb14 was not
present in the precipitate. Similarly, PLCc ability to co-precipitate
FGFR was suppressed by the Y766 mutation. In the presence of
the FGFR-Y766F mutant, PLCc was also unable to recruit Grb14.
These data suggest that Grb14 and PLCc do not directly interact
and that the formation of a ternary complex requires FGFR kinase
activity and a phosphorylated Y766 motif.
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To further study the molecular mechanism involved in Grb14
effect on FGFR signaling, we then took advantage of the Xenopus
oocyte model. Oocytes are physiologically arrested at the G2 stage
of the ﬁrst meiosis prophase, and entry into the M phase can be in-
duced by the natural inducer progesterone or by insulin [21,22].
Xenopus oocytes are devoided of endogenous FGFR but these recep-
tors can be expressed by injecting FGFR (or PDGFR-FGFR chimera)
cRNA, and FGF (or PDGF-BB) stimulation of FGFR-expressing
oocytes leads to oocyte maturation (as evidenced by the GVBD),
through a PLCc-dependent mechanism [12,23]. Furthermore, injec-
tion of Grb14 inhibits FGF- but not progesterone-induced GVBD,
demonstrating that oocytes are a useful model to study Grb14 ef-
fect on FGFR signaling [8,9].
FGFR-expressing oocytes were injected or not with 75 ng of
puriﬁed GST-Grb14 one hour before growth factor stimulation
and FGFR immunoprecipitation. Intracellular Grb14 concentration
was therefore in a range similar to endogenous signaling proteins
such as PKA or Rsk2 (respectively 0.8 lM vs 1.5 lM and 0.12 lM)
[24,25]. Ligand stimulation induced PLCc and Grb14 binding to
the receptor (Fig. 2A). Interestingly, FGF-induced phosphorylation
of PLCc on its Y783 residue, a phosphorylation site essential forBA
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Fig. 2. Grb14 inhibits FGF-induced PLCc activation in FGFR-expressing Xenopus oocy
microinjected with the indicated GST-fusion proteins or peptides, and stimulated or no
immunodetected using antibodies indicated on the left part of the blots. (B) Membrane
oocytes expressing PDGF-FGFR chimera for 48 h and injected with 75 ng of GST-Grb14 (u
E indicates that the phosphopeptide was pre-incubated with Grb14 for 1 h before the micits activation [26], was inhibited in the presence of Grb14. In agree-
ment with the absence of PLCc phosphorylation, Grb14 also inhib-
ited FGFR-dependent PLCc/calcium-activated chloride current
(Fig. 2B) [27] as well as FGFR-dependent GVBD (Supplementary
Table 1). These data indicate that Grb14 recruitment does not
inhibit PLCc binding to the FGFR but blocked its subsequent phos-
phorylation and activation. It can be noticed that trapping endog-
enous PLCc by the injection of anti-PLCc antibodies inhibited its
interaction with the receptor and oocyte maturation, but did not
block Grb14 binding to the stimulated FGFR, indicating that
Grb14 recruitment to the receptor was not dependent on PLCc
availability (Supplementary Fig. S3A and Supplementary Table 1).
We then investigated the role of the Y766 residue in the forma-
tion of the FGFR-Grb14 complex in the oocyte system. Expression
of a FGFR-Y766F mutant abolished the co-immunoprecipitation
of the activated receptor with both PLCc and Grb14 (Fig. 2C). Injec-
tion of a phosphopeptide Pep-pY766 prior to hormonal stimulation
inhibited ligand-induced PLCc binding to the receptor (Fig. 2D) and
oocyte maturation (Supplementary Table 1), probably by trapping
PLCc. However, pre-incubation of Pep-pY766 with Grb14 before
injection into the oocytes prevented Grb14 interaction with the
receptor, and rescued PLCc binding and Y783 phosphorylation as
well as oocyte maturation. Interestingly, pre-incubation of an ex-2 min
20 nA
Grb14
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roinjection. GST-Grb14-SH2 fusion was immunorevealed using anti-GST-antibodies.
E. Browaeys-Poly et al. / FEBS Letters 584 (2010) 4383–4388 4387cess of Pep-pY766 (30 ng) with Grb14 prevented binding of both
Grb14 and PLCc to FGFR, suggesting that the amount of peptide
not complexed with Grb14 remained available to block PLCc
recruitment to the receptor and subsequent oocyte maturation.
Similar experiments performed with a pY776 peptide provided
evidence that this site was not involved in the Grb14–FGFR inter-
action (Fig. 2E and Supplementary Table 1). The afﬁnities of
Grb14 and PLCc-SH2 domain for the phosphorylated pY766 site
of the FGFR, measured by polarization ﬂuorescence using a ﬂuores-
cent pY766 peptide, were in the same order of magnitude, suggest-
ing that competition for this site may occur in intact cells (kd value
of 1.61 ± 0.23 lM (R2 > 0.85) and 0.21 ± 0.06 lM (R2 > 0.98) for
Grb14 and PLCc SH2 domain, respectively).
All together these data support the results obtained in BRET
experiments, showing the recruitment of Grb14 to the activated
FGFR, the role of pY766 in this interaction and the formation of a
trimeric complex containing PLCc, Grb14 and FGFR. Importantly,
these experiments further provide evidence that the presence of
Grb14 in the FGFR-PLCc complex inhibits PLCc tyrosine phosphor-
ylation and activation.
3.3. Molecular analysis of the Grb14-FGFR-PLCc complex
Considering the role of Y766 in the formation of the Grb14-
FGFR complex, we ﬁrst investigated whether the SH2 domain of
Grb14 could mediate FGFR binding. Puriﬁed Grb14-SH2 domain
was injected into FGFR-expressing oocytes, and ligand-stimulated
receptors were immunoprecipitated. Grb14-SH2 domain co-
precipitated with the receptors (Fig. 3A), and this interaction was
abolished by the Y766F mutation or by pre-incubation of the SH2
domain with the pY766 peptide before microinjection into the
oocytes (Fig. 3B). Interestingly, in contrast to the formation of the
trimeric complex observed with the full length Grb14 protein, PLCc
was not present in the FGFR immune complex when the SH2 do-
main was injected. All together these data show that Grb14-SH2
and FGFR-pY766 are both involved the formation of the FGFR-
Grb14 complex, and further suggest that Grb14 domain N-terminalPLC γ
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We then investigated whether Grb14 was able to interact with
PLCc. When Grb14 was injected into naïve oocytes that did not ex-
press FGFR, it did not co-precipitate with endogenous PLCc
(Fig. 3C). Interestingly, if Grb14 was pre-incubated with the
pY766 phosphopeptide to allow the formation of a Grb14-pY766
complex before its injection, PLCc was then present in the Grb14
immune complex. Injection of the phosphopeptide in the oocytes
1 h before Grb14 did not allow to detect the formation of the
Grb14–PLCc interaction. Thus, prior interaction of Grb14 with
the phosphotyrosine 766 residue is required for its interaction with
PLCc, suggesting that binding to the FGFR-phosphopeptide induces
a modiﬁcation of Grb14 spatial conformation that unmasks a PLCc
binding motif.
The N-terminal domain of Grb14 contains a polyproline-rich
motif (PP) [28]. An attracting hypothesis is that binding of the
SH3 domain PLCc to thismotif could be involved in the stabilization
of the trimeric complex. We performed competition experiments
using either a PLCc-SH3 GST-fusion or a Grb14-PP peptide. As
shown in Fig. 3D, co-injection of the PLCc-SH3 domain or of the
PP peptide inhibited the recruitment of endogenous PLCc into the
FGFR immune complex when Grb14 was present, whereas it had
no effect in the absence of Grb14. These results suggest that the
Grb14-PP motif and PLCc-SH3 domain are involved in the forma-
tion of the trimeric FGFR-PLCc-Grb14 complex.
All together these data lead to propose an original molecular
mechanism for the inhibition of FGF signaling by Grb14. FGF stim-
ulation induces Grb14 interaction with FGFR through the binding
of the Grb14-SH2 domain to the phosphorylated Y766 residue of
the receptor, and this recruitment inhibits the tyrosine phosphor-
ylation and activation of PLCc. Recruitment of Grb14 induces a
modiﬁcation of the FGFR–PLCc interaction, as shown in Fig. 1F,
but the molecular interactions involved in the stabilization of the
receptor complex remain to be clariﬁed. Grb14 and PLCc SH2 do-
mains display similar afﬁnity for the FGFR pY766 motif. Structural
studies indicate that a single phosphotyrosine residue cannot
interact simultaneously with two SH2 domains, suggesting thatWT             Y766F
IP: anti-receptor
PLCγ
Grb14-SH2
FGFR
+
-
-
+
+
- +
+
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4388 E. Browaeys-Poly et al. / FEBS Letters 584 (2010) 4383–4388in the trimeric complex with the FGFR Grb14 and PLCc do not bind
to the same pY766 residue. Since FGFR activation results in its
dimerization, an alternative hypothesis is that PLCc and Grb14
are bound through their SH2 domain to each pY766 residues of
the two adjacent chains of the receptor dimer. In this conﬁguration
PLCc would still be phosphorylatable. However, as shown in Fig. 2,
PLCc tyrosine-phosphorylation is abolished when Grb14 is present,
although the kinase activity of the receptor is not inhibited, as at-
tested by the detection of Grb2 in the activated receptor complex.
Indeed, under FGF stimulation, Grb2 does not directly bind to the
receptor, but interacts with Shc and/or FRS2 which are tyrosine
phosphorylated by the FGFR and bound to the receptor [29]. This
suggests that in the FGFR-PLCc-Grb14 trimeric complex the kinase
of the receptor is active, but the Y783 residue of PLCc can no more
reach the catalytic site of the receptor. This could be due to a reori-
entation of the protein which would still be bound to the FGFR
tyrosine kinase domain through its secondary SH2 motif binding
[30], and/or to a displacement of PLCc from FGFR to Grb14 through
its interaction with the Grb14 N-terminal PP motif. Our study sug-
gests then that, in contrast to its effect on insulin signaling, Grb14
does not inhibit FGFR catalytic activity but exerts a more speciﬁc
inhibition on the PLCc signaling pathway.
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